We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 6 of 26 for:    baeten

Initial Treatment With Golimumab in Early PsA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01871649
Recruitment Status : Completed
First Posted : June 7, 2013
Last Update Posted : November 26, 2018
Information provided by (Responsible Party):
D.L.P. Baeten, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Brief Summary:

The investigators will perform a 22-week randomized, double-blind, placebo-controlled trial of golimumab + methotrexate (MTX) versus methotrexate alone in methotrexate-naïve patients with Psoriatic Arthritis (PsA). Afterwards, a 28 week open label phase with methotrexate alone is started. Golimumab will be discontinued.


First, the investigators hypothesize that initiation of a combination therapy with golimumab + MTX will be safe and superior to MTX alone in MTX-naïve PsA patients, as assessed by the percentage of patients achieving Disease Activity Score (the investigators hypothesize that more patients with the early combination treatment will respond (according to Disease Activity Score (DAS), American college of Rheumatology (ACR), or Psoriatic Arthritis Response Criteria (PsARC) responses) and achieve a state of Low Disease Activity (LDA) or Minimal Disease Activity (MDA) than patients on MTX alone.

Third, the investigators hypothesize that a significant proportion of the patients will continue to benefit from this early aggressive treatment initiation even after stopping golimumab treatment.

Condition or disease Intervention/treatment Phase
Psoriatic Arthritis Drug: golimumab Drug: methotrexate Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Trial of Golimumab+Methotrexate Versus Methotrexate Alone in Methotrexate-naïve Patients With Psoriatic Arthritis
Actual Study Start Date : August 2013
Actual Primary Completion Date : November 2018
Actual Study Completion Date : November 2018

Arm Intervention/treatment
Active Comparator: methotrexate
methotrexate is the active comparator, it will be compared to golimumab + methotrexate
Drug: methotrexate
Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.

Experimental: golimumab and methotrexate
The combination of golimumab en methotrexate will be compared to methotrexate alone.
Drug: golimumab
golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
Other Name: simponi

Primary Outcome Measures :
  1. Percentage of patients achieving DAS remission response criteria [ Time Frame: week 22 ]

    1. To demonstrate that golimumab + MTX is superior to MTX alone in achieving DAS remission in MTX naïve PsA patients at week 22

    DAS = Disease activity score, remission is defined as a DAS < 1.6

  2. Number of Participants with Adverse Events [ Time Frame: week 22 ]

    Number of patients with(severe) adverse events (and type) during the study period.

    Safety will be monitored during the study period by laboratory tests and physical examination.

Secondary Outcome Measures :
  1. Number of patients fulfilling Minimal Disease activity criteria and other outcome measurements [ Time Frame: week 22 ]
    To demonstrate that golimumab + MTX is superior to MTX alone as assessed by DAS, ACR and PsARC responses, as well as by achievement of low disease activity (LDA, as defined by DAS<2.4) and minimal disease activity (MDA, as defined by Coates et al, Ann Rheum Dis 2010). Also the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) score and Psoriasis Area Severity Index (PASI) score will be determined in MTX naïve PsA patients at week 22.

Other Outcome Measures:
  1. Efficacy after withdrawing anti-TNF [ Time Frame: week 50 ]
    To demonstrate that initial treatment of MTX naïve patients with golimumab + MTX is superior to MTX alone to maintain DAS (disease activity score) remission, LDA (Low Disease Activity) and MDA over time (up to week 50) after withdrawing golimumab.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prior to any study procedure, voluntary written informed consent must be obtained, after the nature and purpose of this study were explained
  • Patients should be between 18 and 70 years of age at time of consent
  • Patients must have a diagnosis of PsA according to the Classification for psoriatic Arthritis (CASPAR) classification criteria (see Appendix 1).
  • The patient must have an active disease as defined by 3 swollen and 3 tender joints.
  • The use of a stable dose of concomitant nonsteroidal antiinflammatory drug (NSAIDs) and/or corticosteroids is allowed. The dose of corticosteroids should not exceed a prednisone equivalent of 10 mg/day and must be stable for at least 4 weeks prior to baseline. The dose of concomitant NSAIDs and corticosteroids should be kept stable during the whole study period.
  • Patients are considered to be in generally good health based upon the result of a medical history, physical examination, laboratory profile, chest X-ray and electrocardiography (ECG).

Exclusion Criteria:

  • Patient has a concomitant rheumatic condition other than PsA
  • Positivity for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti CCP) antibodies (ACPA)
  • Current or previous use of methotrexate
  • Current use of other Disease Modifying Antirheumatic drug (DMARDs) (sulphasalazine or leflunomide).
  • Prior use of other DMARDs (sulphasalazine or leflunomide) within 3 months before baseline.
  • Current or previous use of biologicals, including Tumor Necrosis Factor (TNF) blocking therapy
  • Patient has active tuberculosis. A purified protein derivative (PPD) skin test and chest X-ray at screening should be negative (in case of latent tuberculosis, a patient may enter the study if prophylaxis with isoniazide is begun prior to administration of study medication). If a patient has an adequately treated tuberculosis in the past, he/she may enter the trial.
  • Patient has received an intra-articular injection with corticosteroids within 4 weeks prior to baseline.
  • Patient has a malignancy (other than basal cell carcinoma of the skin) in the past 5 years
  • Patients has a recent history of (or persistent) infection requiring hospitalization or antibiotic treatment within 4 weeks of baseline Patient has a significant history of cardiac, pulmonary, renal (glomerular filtration rate <40ml/min), hepatic (liver cirrhosis), hematological, neurological, metabolic or any other disease that may affect his/her participation in this study. This should be decided by the opinion of the investigator.
  • All females of childbearing potential must use appropriate contraception, be postmenopausal or surgically sterile. A urine pregnancy-test beta-human chorion gonadotropin (Beta-HCG) will be performed at screening and has to be negative.
  • Subject is pregnant or a breastfeeding woman
  • Liver disease or liver injury as indicated by abnormal liver function tests such as Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), gammaglutamyl transpeptidase (GGT), alkaline phosphatase, or serum bilirubin. The Investigator should be guided by the following criteria: Any single parameter may not exceed 2 x upper limit of normal (ULN).

A single parameter elevated up to and including 2 x ULN should be rechecked once more if elevation levels are found clinically relevant according to the physician, at least prior to enrolment.

- Patient is, in the opinion of the investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01871649

Layout table for location information
Amsterdam, Noord Holland, Netherlands, 1056 AB
Academic Medical Center/University of Amsterdam
Amsterdam, Noord Holland, Netherlands, 1105 AZ
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Layout table for investigator information
Principal Investigator: Dominique LP Baeten, Prof. dr. MD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: D.L.P. Baeten, prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT01871649    
Other Study ID Numbers: AMC_ 42670_PsA_Golimumab
First Posted: June 7, 2013    Key Record Dates
Last Update Posted: November 26, 2018
Last Verified: November 2018
Keywords provided by D.L.P. Baeten, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
psoriatic arthritis
minimal disease activity
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spinal Diseases
Bone Diseases
Skin Diseases, Papulosquamous
Skin Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors
Tumor Necrosis Factor Inhibitors